CTLA4 and neoplasm: Ipilimumab binds to CTLA-4 on T cells, which enhances the anti-tumour immune response, whereas monoclonal antibodies such as Pembrolizumab and Nivolumab exert anti-tumour immune response by blocking PD-1 and PD-L1 signalling [38].